Independent education on GLP-1 weight-loss drugs, muscle preservation, and metabolic health. All claims cited to primary sources.
What the preclinical literature shows about BPC-157: gut healing, connective tissue repair, angiogenesis mechanisms, and the July 2026 FDA regulatory review.
Read →CJC-1295 and ipamorelin activate two separate GH-release pathways. Research since 1990 documents their combination produces substantially more GH than either alone.
Read →TruDiagnostic's TruAge measures DNA methylation to estimate biological age. Here's what the science shows — and why it matters for GLP-1 users.
Read →GLP-1 drugs cause 40–45% lean mass loss on average. Here's the science behind why — and the evidence-based strategies most worth your attention.
Read →GLP-1 users typically eat less than half the protein their muscles need. Here's the research-backed target, why the gap is so common, and how to close it.
Read →Clinical trials favor tirzepatide for muscle preservation. The largest real-world study says semaglutide wins. Here's what both show — and what matters most.
Read →